Albertí-Servera Llucia, Demeyer Sofie, Govaerts Inge, Swings Toon, De Bie Jolien, Gielen Olga, Brociner Marco, Michaux Lucienne, Maertens Johan, Uyttebroeck Anne, De Keersmaecker Kim, Boeckx Nancy, Segers Heidi, Cools Jan
Center for Human Genetics, KU Leuven, Leuven, Belgium.
Center for Cancer Biology, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium.
Blood. 2021 Feb 11;137(6):801-811. doi: 10.1182/blood.2020006996.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive leukemia that is most frequent in children and is characterized by the presence of few chromosomal rearrangements and 10 to 20 somatic mutations in protein-coding regions at diagnosis. The majority of T-ALL cases harbor activating mutations in NOTCH1 together with mutations in genes implicated in kinase signaling, transcriptional regulation, or protein translation. To obtain more insight in the level of clonal heterogeneity at diagnosis and during treatment, we used single-cell targeted DNA sequencing with the Tapestri platform. We designed a custom ALL panel and obtained accurate single-nucleotide variant and small insertion-deletion mutation calling for 305 amplicons covering 110 genes in about 4400 cells per sample and time point. A total of 108 188 cells were analyzed for 25 samples of 8 T-ALL patients. We typically observed a major clone at diagnosis (>35% of the cells) accompanied by several minor clones of which some were less than 1% of the total number of cells. Four patients had >2 NOTCH1 mutations, some of which present in minor clones, indicating a strong pressure to acquire NOTCH1 mutations in developing T-ALL cells. By analyzing longitudinal samples, we detected the presence and clonal nature of residual leukemic cells and clones with a minor presence at diagnosis that evolved to clinically relevant major clones at later disease stages. Therefore, single-cell DNA amplicon sequencing is a sensitive assay to detect clonal architecture and evolution in T-ALL.
T细胞急性淋巴细胞白血病(T-ALL)是一种侵袭性白血病,在儿童中最为常见,其特征是在诊断时几乎没有染色体重排,蛋白质编码区域有10至20个体细胞突变。大多数T-ALL病例存在NOTCH1激活突变以及与激酶信号传导、转录调控或蛋白质翻译相关的基因突变。为了更深入了解诊断时和治疗期间的克隆异质性水平,我们使用Tapestri平台进行单细胞靶向DNA测序。我们设计了一个定制的ALL检测板,对每个样本和时间点约4400个细胞中的305个覆盖110个基因的扩增子进行了准确的单核苷酸变异和小插入缺失突变检测。对8例T-ALL患者的25个样本共108188个细胞进行了分析。我们通常在诊断时观察到一个主要克隆(>35%的细胞),同时伴有几个次要克隆,其中一些次要克隆占细胞总数的比例不到1%。4例患者有>2个NOTCH1突变,其中一些存在于次要克隆中,这表明在发育中的T-ALL细胞中获得NOTCH1突变的压力很大。通过分析纵向样本,我们检测到了残留白血病细胞和在诊断时少量存在但在疾病后期发展为临床相关主要克隆的克隆的存在及其克隆性质。因此,单细胞DNA扩增子测序是检测T-ALL克隆结构和演变的一种灵敏方法。